Photo source: Piper Report
The White House has been in talks with Pelosi’s office for months on drug prices, a rare shared priority, but the effort always faced tough odds given the partisan divide and the impeachment inquiry into President Trump.
Now the Trump administration is downplaying the chances it will endorse Pelosi’s bill, instead pointing to a somewhat more modest bill in the Senate from Sens.Chuck Grassley(R-Iowa) andRon Wyden(D-Ore.), the chairman and ranking member, respectively, of the Senate Finance Committee.
“Lines of communication remain open with the Speaker’s office, but the Grassley-Wyden proposal is the most likely solution that could advance on a bipartisan basis and achieve the President’s priority of lowering drug prices even further for all Americans,” White House spokesman Judd Deere wrote in an email.
Read more: White House distances itself from Pelosi plan to lower drug prices
